CD4 and type 2 diabetes mellitus: IL-6 is a pleiotropic cytokine that is considered to be a biomarker of inflammation [51] and a therapeutic target for the treatment of T2D [52]; thus, it is possible that IL-6 may act in a similar way to IL-12, determining the differentiation of naive CD4 T cells toward effector cells [53].